Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
2.210
+0.120 (5.74%)
Nov 21, 2024, 11:16 AM EST - Market open
Adagene Employees
Adagene had 174 employees as of December 31, 2023. The number of employees decreased by 74 or -29.84% compared to the previous year.
Employees
174
Change (1Y)
-74
Growth (1Y)
-29.84%
Revenue / Employee
$4,688
Profits / Employee
-$183,042
Market Cap
97.84M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 174 | -74 | -29.84% |
| Dec 31, 2022 | 248 | -11 | -4.25% |
| Dec 31, 2021 | 259 | 61 | 30.81% |
| Dec 31, 2020 | 198 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Akoya Biosciences | 330 |
| Karyopharm Therapeutics | 325 |
| Seres Therapeutics | 233 |
| Fractyl Health | 102 |
| Immunic | 77 |
| Assembly Biosciences | 65 |
| InflaRx | 62 |
| Journey Medical | 41 |
ADAG News
- 14 days ago - Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewsWire
- 6 weeks ago - Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewsWire
- 2 months ago - Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) - GlobeNewsWire
- 4 months ago - Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September - GlobeNewsWire
- 6 months ago - Adagene to Present at Investor Conferences in June - GlobeNewsWire
- 8 months ago - Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 months ago - Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board - GlobeNewsWire
- 9 months ago - Adagene to Present at the Leerink Partners Global Biopharma Conference 2024 - GlobeNewsWire